| ID | Type | Description | Link |
|---|---|---|---|
| 01-C-0049 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background:
NSC630176 is a depsipeptide fermentation product from Chromobacterium violaceum with potent cytotoxic activity against human tumor cell lines and in vivo efficacy against both human tumor xenografts and murine tumors (1-3).
NSC 630176, herein referred to as depsipeptide, shows a lack of cross resistance with several commonly used cytotoxic agents such as vincristine, 5-fluorouracil, mitomycin C and cyclophosphamide (2). However, it has been defined as a P-glycoprotein (Pgp) substrate by COMPARE analysis of the National Cancer Institute (NCI) drug screen cytotoxicity profile (4).
Depsipeptide is a member of a novel class of antineoplastic agents, the histone deacetylase inhibitors.
In the phase I trial conducted at the National Cancer Institute (NCI), responses were observed at the maximum tolerated dose (MTD) in patients with cutaneous and peripheral T-cell lymphoma.
Objectives:
In patients with cutaneous T-cell lymphoma, the primary end points to be examined are overall response rate, complete response rate and duration of response.
In patients with relapsed peripheral T-cell lymphoma, the endpoints to be examined are overall response rate and complete response rate.
To evaluate the tolerability of depsipeptide with extended cycles of therapy.
Eligibility:
Patients with cutaneous T-cell lymphoma (mycosis fungoides or Sezary syndrome) or other peripheral T-cell lymphomas are eligible.
Design:
Depsipeptide will be administered at 14 mg/m^2, over 4 hours on days 1, 8 and 15.
This trial will accrue in six cohorts; Arm 1, patients with cutaneous T-cell lymphoma who have had less than or equal to two prior cytotoxic chemotherapy regimens; Arm 2, patients with peripheral T-cell lymphoma who have had less than or equal to two prior cytotoxic chemotherapy regimens; Arm 3, patients with cutaneous and peripheral T-cell lymphoma who have had more than two prior cytotoxic chemotherapy regimens; Arm 4, patients with other mature T-cell lymphomas; Arm 5, a replicate arm of arm 1; Arm 6, patients with peripheral T-cell lymphoma who have had more than two prior cytotoxic chemotherapy regimens; Arm 7, patients with cutaneous T cell lymphoma who have received vorinostat.
Dose may be adjusted based on toxicities.
Background:
NSC630176 is a depsipeptide fermentation product from Chromobacterium violaceum with potent cytotoxic activity against human tumor cell lines and in vivo efficacy against both human tumor xenografts and murine tumors (1-3).
NSC 630176, herein referred to as depsipeptide, shows a lack of cross resistance with several commonly used cytotoxic agents such as vincristine, 5-fluorouracil, mitomycin C and cyclophosphamide (2). However, it has been defined as a P-glycoprotein (Pgp) substrate by COMPARE analysis of the National Cancer Institute (NCI) drug screen cytotoxicity profile (4).
Depsipeptide is a member of a novel class of antineoplastic agents, the histone deacetylase inhibitors.
In the phase I trial conducted at the NCI, responses were observed at the maximum tolerated dose (MTD) in patients with cutaneous and peripheral T-cell lymphoma.
Objectives:
In patients with cutaneous T-cell lymphoma, the primary end points to be examined are overall response rate, complete response rate and duration of response.
In patients with relapsed peripheral T-cell lymphoma, the endpoints to be examined are overall response rate and complete response rate.
To evaluate the tolerability of depsipeptide with extended cycles of therapy.
Eligibility:
Patients with cutaneous T-cell lymphoma (mycosis fungoides or Sezary syndrome) or other peripheral T-cell lymphomas are eligible.
Design:
Depsipeptide will be administered at 14 mg/m^2, over 4 hours on days 1, 8 and 15.
This trial will accrue in six cohorts; Arm 1, patients with cutaneous T-cell lymphoma who have had less than or equal to two prior cytotoxic chemotherapy regimens; Arm 2, patients with peripheral T-cell lymphoma who have had less than or equal to two prior cytotoxic chemotherapy regimens; Arm 3, patients with cutaneous and peripheral T-cell lymphoma who have had more than two prior cytotoxic chemotherapy regimens; Arm 4, patients with other mature T-cell lymphomas; Arm 5, a replicate arm of arm 1; Arm 6, patients with peripheral T-cell lymphoma who have had more than two prior cytotoxic chemotherapy regimens; Arm 7, patients with cutaneous T cell lymphoma who have received vorinostat.
Dose may be adjusted based on toxicities.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Peripheral T-cell Lymphoma (PTCL) | Experimental | Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle. |
|
| Cutaneous T-cell Lymphoma (CTCL) | Experimental | Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Romidepsin | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With a Response | A rigorous composite assessment was employed with uni-dimensional measurements of skin and visceral disease sites assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) required clearing of all known disease sites. Partial response (PR) required documented response in skin (≥ 30% per RECIST) or lymph nodes (≥ 50% per the International Working Group (IWG) criteria, with response in both compartments for a determination of PR, IWG guidelines. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the target lesions, or the appearance of one or more new lesions. Lymph node disease was assessed bi-dimensionally using the IWG criteria. Bone marrow involvement, as recommended by IWG criteria, and presence of circulating malignant T-cells ascertained by flow cytometry. | up to 56.5 days |
| Duration of Response (DOR) | DOR is defined as the date response was noted until disease was no longer considered to be responding. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and the International Working Group Criteria (IWG).Complete response (CR) required clearing of all known disease sites. Partial response (PR) required documented response in skin (≥ 30% per RECIST) or lymph nodes (≥ 50% per the International Working Group (IWG) criteria, with response in both compartments for a determination of PR, IWG guidelines. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the target lesions, or the appearance of one or more new lesions. Lymph node disease was assessed bi-dimensionally using the IWG criteria. Bone marrow involvement, as recommended by IWG criteria, and presence of circulating malignant T-cells ascertained by flow cytometry. | up to 127 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Adverse Events | Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. | 147 months and 5 days |
| Median Number of Cycles of Depsipeptide Administered |
Not provided
Based on the Inclusion Criteria outlined below, patients will accrue to one of the cohorts of the trial.
Cohort- chemotherapy regimens allowed. Cohort Status
Cohort 1
Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome)-2 or fewer. Closed to accrual
Cohort 2
Peripheral T-cell Lymphoma, unspecified, or Anaplastic large cell lymphoma (T and null cell) Primary Cutaneous Type -2 or fewer. Open and accruing
Cohort 3
Cutaneous T-cell Lymphomas or Peripheral T-cell Lymphoma-More than 2. Closed to accrual
Cohort 4
Other Mature T cell Lymphomas-Any number. Open and accruing
Cohort 5
Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome)-2 or fewer-Cohort 5 is a replicate cohort, identical to #1
Cohort 6
Peripheral T-cell Lymphoma (PTCL), unspecified, or Anaplastic large cell lymphoma (T and null cell) Primary Cutaneous Type-More than 2. Patients with PTCL in cohort 3 migrated to this cohort
Cohort 7
Cutaneous T-cell Lymphoma (mycosis fungoides or Sezary syndrome) Prior vorinostat required-Any number
Patients with cutaneous T-cell lymphoma [CTCL (mycosis fungoides or Sezary syndrome) stage IB to IVB are eligible. Patients with stage IB and IIA should be refractory to, intolerant to, or have reached a six-month or longer response plateau on at least two prior therapies from the following list: psoralen plus ultraviolet A irradiation (PUVA), ultraviolet B (UVB), electron beam therapy (EBT), photophoresis, interferon, systemic cytotoxic chemotherapy, topical nitrogen mustard, or topical carmustine (BCNU). One qualifying prior treatment must have been topical nitrogen mustard, topical carmustine or a phototherapy (UVB, PUVA or EBT). Topical steroids, systemic retinoids or biologicals do not qualify. Patients with stage IB or IIA who are not candidates for topical nitrogen mustard, topical carmustine or phototherapy (UVB, PUVA or EBT) are eligible for enrollment. Patients may not have received more than two systemic cytotoxic chemotherapy regimens. Steroids, retinoids, and biologic agents, will not be considered as systemic cytotoxic chemotherapy. Radiolabeled monoclonal antibody therapy is considered equivalent to a systemic cytotoxic chemotherapy regimen and must be counted toward the two prior systemic cytotoxic regimens. Patients with stage IIB-IVB who have had no more than 2 prior systemic cytotoxic chemotherapeutic regimens are eligible. There is no restriction regarding number of prior topical therapies, skin irradiation, or non-cytotoxic systemic therapies (i.e. PUVA, retinoids or biologic, with the exception of radiolabeled monoclonal antibody therapy) in this patient group. After 24 patients were enrolled in this arm, the arm was closed, and a replicate arm constituted of this same patient population was opened (Cohort 5).
Patients with peripheral T-cell lymphoma (PTCL), unspecified, or anaplastic large cell lymphoma, T and null cell, primary cutaneous type, as defined by the Revised European American Lymphoma (REAL)/World Health Organization (WHO) classification (16-18), who have experienced disease progression after receiving prior standard treatment and who have had no more than 2 prior systemic cytotoxic chemotherapeutic regimens are eligible.
Patients with cutaneous T cell lymphoma (Mycosis fungoides or Sezary Syndrome) or peripheral T cell lymphoma as defined above who have received more than 2 prior systemic therapies and who have experienced disease progression will be included in a third and independent arm. This arm of the protocol was closed to accrual for CTCL with Amendment H.
Patients with mature T cell lymphomas not included above will be enrolled in a fourth arm. These include but are not exclusively limited to: Enteropathy-type T cell lymphoma; Hepatosplenic T-cell lymphoma; Subcutaneous panniculitis-like T cell lymphoma; Angioimmunoblastic T-cell lymphoma; Anaplastic large cell lymphoma. Patients must have experienced disease progression after receiving prior standard treatment. There will be no limit on the number of prior regimens. Primitive T cell neoplasms and T cell leukemias will not be enrolled.
Patients with peripheral T-cell lymphoma, unspecified, or anaplastic large cell lymphoma, T and null cell, primary cutaneous type, as defined by the REAL/WHO classification (16-18), who have experienced disease progression after receiving prior standard treatment and who have had more than 2 prior systemic cytotoxic chemotherapeutic regimens are eligible for enrollment to a sixth arm of the trial.
Patients with cutaneous T cell lymphoma (Mycosis fungoides or Sezary Syndrome) or peripheral T cell lymphoma as defined in #1 who have received any number of prior systemic therapies and who have previously been treated with vorinostat will be included in a third and independent arm. Patients can be enrolled in this arm if they received prior vorinostat and experienced disease progression, subsequent relapse, or had to discontinue to agent due to toxicity.
Disease that is measurable by radiographic imaging, assessing skin lesions, or by quantitating Sezary cell count.
Patients must:
be age greater than or equal to 18 years
have a performance status of Eastern Cooperative Oncology Group (ECOG) 0-2
have no serious or intercurrent illness and have a life expectancy of greater than 12 weeks
give written informed consent
female patients of childbearing potential must have a negative pregnancy test within 4 weeks and must use effective contraception
sexually active males must use effective contraception
Laboratory values (performed less than or equal to 14 days prior to registration):
absolute neutrophil count greater than or equal to 1000/microliter, platelets greater than or equal to l00,000/microliter, bilirubin (total and direct) less than or equal to 1.5x upper limit of normal, and aspartate aminotransferase (AST) less than or equal to 3x upper limit of normal, unless impairment is due to organ involvement by lymphoma, creatinine less than or equal to 1.5x upper limit of normal, or documented creatinine clearance of greater than or equal to 60mL/min
Cardiac studies (performed within 4 weeks of registration):
Ejection fraction of greater than 50% by Echocardiogram or Cardiac magnetic resonance imaging (MRI), or greater than or equal to 45% by multi-gated acquisition scan (MUGA) Scan.
A stable dose (greater than 1 month) of corticosteroids administered for symptom management will not preclude enrollment. Tapering will be initiated following administration of depsipeptide.
EXCLUSION CRITERIA:
Patients with unconfirmed diagnosis, or with B-cell lymphomas will be excluded.
Prior or concurrent malignancies that have not been curatively treated.
Known central nervous system (CNS) lymphoma.
Chemotherapy within 4 weeks, 6 weeks for nitrosoureas or mitomycin C.
Biologics, Immunotherapy within 2 weeks.
Human Immunodeficiency virus (HIV) seropositivity.
Pregnant or breast-feeding patients.
Major surgery within 21 days.
Uncontrolled infection or uncontrolled medical illness.
Patients having received prior histone deacetylase (HDAC) inhibitor therapy for T cell lymphoma will be excluded except for patients eligible to enroll in cohort 7.
Patients with the following cardiac risk factors will be excluded from the study:
Patients with known cardiac abnormalities such as:
Congenital long QT syndrome
Corrected QT interval (QTc) interval greater than 480 milliseconds
Patients who have had a myocardial infarction within 12 months of study entry.
Patients who have active coronary artery disease as, e.g. angina as defined by Canadian Class II-IV
Patients with an electrocardiography (ECG) recorded at screening showing evidence of cardiac ischemia (ST depression of greater than or equal to 2 mm).
Any patient in whom coronary artery disease is suspected should be referred for a cardiology consultation and if active myocardial ischemia is demonstrated the patient should be excluded. If a noninvasive imaging study is equivocal, it may be necessary to proceed to coronary angiography.
Patients with congestive heart failure that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction less than 45% by MUGA scan or less than 50% by echocardiogram and/or MRI.
Patients with a history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD). Patients with a history of arrhythmia should have Holter monitoring and evaluation by cardiology.
Patients with dilated, hypertrophic, or restrictive cardiomyopathy from prior treatment or other causes (in doubt, see ejection fraction criteria above). Patients with left ventricular hypertrophy should be discussed with the Principal Investigator or Study Chairman.
Patients with uncontrolled hypertension, i.e., systolic blood pressure (SBP) greater than or equal to 160 mm Hg or diastolic blood pressure (DBP) greater than or equal to 95 mm Hg.
Patients with cardiac arrhythmia requiring anti-arrhythmic medication other than beta blocker or calcium channel blocker. Patients in whom digitalis cannot be discontinued are excluded from study.
Patients with Mobitz II second degree heart block who do not have a pacemaker. Patients with first degree or Mobitz I second degree heart block, bradyarrhythmias or sick sinus syndrome require Holter monitoring and evaluation by cardiology.
Patients with other cardiac disease may be excluded at the discretion of the principal investigator (PI) following consultation with cardiology.](streamdown:incomplete-link)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| James Gulley, M.D. | National Cancer Institute (NCI) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic Scottsdale | Scottsdale | Arizona | 85259 | United States | ||
| University of Arkansas |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16778104 | Background | Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006 Jun 15;12(12):3762-73. doi: 10.1158/1078-0432.CCR-05-2095. | |
| 19228751 | Background | Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503. doi: 10.1158/1078-0432.CCR-08-1215. |
| Label | URL |
|---|---|
| NIH Clinical Center Detailed Web Page | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Although 7 cohorts were written in the protocol, the cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Peripheral T-cell Lymphoma (PTCL) | Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle. |
| FG001 | Cutaneous T-cell Lymphoma (CTCL) |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants were administered Depsipeptide and cycles (each cycle is 21 days) were monitored from the prescribed dose or higher to determine reductions (if needed) to maintain tolerability.
| 83 cycles (i.e., each cycle is 21 days) |
| Time to Progression | Time to progression is defined from the first day of therapy until documentation of progressive disease. Progressive disease (PD) is at least a 20% increase in the sum of the target lesions, or the appearance of one or more new lesions. Lymph node disease was assessed bi-dimensionally using the International Working Group (IWG) criteria. Bone marrow involvement, as recommended by IWG criteria, and presence of circulating malignant T-cells ascertained by flow cytometry. | Until disease progression, or 30 days following off study date |
| Fold Change in Histone Acetylation | Fold change is calculated by dividing the level of histone acetylation in a treated sample (at 4, 24, and 48 hours) measured as intensity on a dot blot immunoassay, divided by the intensity in the pre-treatment sample. We considered a ≥ 2-fold change a measurable difference, and indicative of successful HDAC inhibition by romidepsin (depsipeptide). | 4 hours, 24 hours, and 48 hours after Romidepsin |
| Multidrug Resistance Protein 1 (MDR1) or ATP-binding Cassette Sub-family B Member 1 (ABCB1) Gene Expression | Total ribonucleic acid (RNA) was isolated from peripheral blood mononuclear cells or patient tissue biopsies and analyzed by quantitative polymerase chain reaction (qPCR). Expression of MDR-1/ABCB1 was determined by qPCR relative to an RNA standard, then normalized to ribosomal RNA (rRNA). Fold change is calculated by dividing the level of MDR-1 in a treated sample (at 4, 24, and 48 hours) measured by qPCR, divided by MDR-1 in the pre-treatment sample. We considered a ≥ 2-fold change a measurable difference, and indicative of successful HDAC inhibition by romidepsin (depsipeptide). | 4 hours, 24 hours, and 48 hours after Romidepsin |
| Little Rock |
| Arkansas |
| 72205 |
| United States |
| City of Hope National Cancer Center | Duarte | California | 91010 | United States |
| Mercy General Hospital | Sacramento | California | 95819 | United States |
| Georgetown University | Washington D.C. | District of Columbia | 20007-2197 | United States |
| Northwestern University | Chicago | Illinois | 60611 | United States |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | United States |
| North Shore University Hospital | Manhasset | New York | 11030 | United States |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15261 | United States |
| West Virginia University | Morgantown | West Virginia | 26506 | United States |
| Royal Adelaide Hospital | Adelaide | Australia |
| Peter MacCallum Cancer Centre | Melbourne | Australia |
| Sir Charles Gairdner Hospital | Perth | Australia |
| 19608677 | Background | Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica. 2009 Nov;94(11):1618-22. doi: 10.3324/haematol.2009.008607. Epub 2009 Jul 16. |
| 19874311 | Background | Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol. 2010 Jan;148(2):256-67. doi: 10.1111/j.1365-2141.2009.07954.x. Epub 2009 Oct 28. |
| 22372971 | Background | Akilov OE, Grant C, Frye R, Bates S, Piekarz R, Geskin LJ. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions. Br J Dermatol. 2012 Jul;167(1):194-7. doi: 10.1111/j.1365-2133.2012.10905.x. |
| 23589175 | Background | Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Clin Cancer Res. 2013 Jun 1;19(11):3095-104. doi: 10.1158/1078-0432.CCR-13-0109. Epub 2013 Apr 15. |
| 25891346 | Result | Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S, Prince HM, Kirschbaum MH, Allen SL, Zain J, Geskin LJ, Joske D, Popplewell L, Cowen EW, Jaffe ES, Nichols J, Kennedy S, Steinberg SM, Liewehr DJ, Showe LC, Steakley C, Wright J, Fojo T, Litman T, Piekarz RL. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol. 2015 Jul;170(1):96-109. doi: 10.1111/bjh.13400. Epub 2015 Apr 19. |
| 19826128 | Result | Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5410-7. doi: 10.1200/JCO.2008.21.6150. Epub 2009 Oct 13. |
| 21355097 | Result | Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011 Jun 2;117(22):5827-34. doi: 10.1182/blood-2010-10-312603. Epub 2011 Feb 25. |
| 28264616 | Derived | Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma. 2017 Oct;58(10):2335-2341. doi: 10.1080/10428194.2017.1295143. Epub 2017 Mar 7. |
Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Although 7 cohorts were written in the protocol, the cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Peripheral T-cell Lymphoma (PTCL) | Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle. |
| BG001 | Cutaneous T-cell Lymphoma (CTCL) | Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With a Response | A rigorous composite assessment was employed with uni-dimensional measurements of skin and visceral disease sites assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR) required clearing of all known disease sites. Partial response (PR) required documented response in skin (≥ 30% per RECIST) or lymph nodes (≥ 50% per the International Working Group (IWG) criteria, with response in both compartments for a determination of PR, IWG guidelines. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the target lesions, or the appearance of one or more new lesions. Lymph node disease was assessed bi-dimensionally using the IWG criteria. Bone marrow involvement, as recommended by IWG criteria, and presence of circulating malignant T-cells ascertained by flow cytometry. | Two participants were excluded. After further analysis it was determined that the participants did not have PTCL but a different form of lymphoma that was not known at the onset of enrollment. | Posted | Number | participants | up to 56.5 days |
|
|
| ||||||||||||||||||||||||||||||||||||
| Primary | Duration of Response (DOR) | DOR is defined as the date response was noted until disease was no longer considered to be responding. Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and the International Working Group Criteria (IWG).Complete response (CR) required clearing of all known disease sites. Partial response (PR) required documented response in skin (≥ 30% per RECIST) or lymph nodes (≥ 50% per the International Working Group (IWG) criteria, with response in both compartments for a determination of PR, IWG guidelines. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Progressive disease (PD) is at least a 20% increase in the sum of the target lesions, or the appearance of one or more new lesions. Lymph node disease was assessed bi-dimensionally using the IWG criteria. Bone marrow involvement, as recommended by IWG criteria, and presence of circulating malignant T-cells ascertained by flow cytometry. | Posted | Median | Full Range | Months | up to 127 months |
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Number of Participants With Adverse Events | Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. | Posted | Number | participants | 147 months and 5 days |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Median Number of Cycles of Depsipeptide Administered | Participants were administered Depsipeptide and cycles (each cycle is 21 days) were monitored from the prescribed dose or higher to determine reductions (if needed) to maintain tolerability. | Posted | Median | Full Range | Cycles per patient | 83 cycles (i.e., each cycle is 21 days) |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Time to Progression | Time to progression is defined from the first day of therapy until documentation of progressive disease. Progressive disease (PD) is at least a 20% increase in the sum of the target lesions, or the appearance of one or more new lesions. Lymph node disease was assessed bi-dimensionally using the International Working Group (IWG) criteria. Bone marrow involvement, as recommended by IWG criteria, and presence of circulating malignant T-cells ascertained by flow cytometry. | Posted | Median | 95% Confidence Interval | Months | Until disease progression, or 30 days following off study date |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Fold Change in Histone Acetylation | Fold change is calculated by dividing the level of histone acetylation in a treated sample (at 4, 24, and 48 hours) measured as intensity on a dot blot immunoassay, divided by the intensity in the pre-treatment sample. We considered a ≥ 2-fold change a measurable difference, and indicative of successful HDAC inhibition by romidepsin (depsipeptide). | Global histone acetylation of all samples at pretreatment was designated as 1; values at other time points for each patient were calculated relative to the corresponding pretreatment value. | Posted | Median | Full Range | Fold change | 4 hours, 24 hours, and 48 hours after Romidepsin |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Multidrug Resistance Protein 1 (MDR1) or ATP-binding Cassette Sub-family B Member 1 (ABCB1) Gene Expression | Total ribonucleic acid (RNA) was isolated from peripheral blood mononuclear cells or patient tissue biopsies and analyzed by quantitative polymerase chain reaction (qPCR). Expression of MDR-1/ABCB1 was determined by qPCR relative to an RNA standard, then normalized to ribosomal RNA (rRNA). Fold change is calculated by dividing the level of MDR-1 in a treated sample (at 4, 24, and 48 hours) measured by qPCR, divided by MDR-1 in the pre-treatment sample. We considered a ≥ 2-fold change a measurable difference, and indicative of successful HDAC inhibition by romidepsin (depsipeptide). | ABCB1 expression of all samples at pretreatment was designated as 1; values at other time points for each patient were calculated relative to the corresponding pretreatment value. | Posted | Median | Full Range | Fold change | 4 hours, 24 hours, and 48 hours after Romidepsin |
|
147 months and 5 days
Although 7 cohorts were written in the protocol, the cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Peripheral T-cell Lymphoma (PTCL) | Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle. | 6 | 47 | 20 | 47 | 47 | 47 |
| EG001 | Cutaneous T-cell Lymphoma (CTCL) | Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m^2 and at 17.5 mg/m^2 on days 1, 8, and 15 of a 28 day cycle. | 5 | 84 | 38 | 84 | 83 | 84 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ANC (absolute neutrophil count) | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Death/ARDS (acute respiratory distress syndrome) | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Anorexia | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Death/Cardiac arrest | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Cardiac troponin T | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Catheter-related infection | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Confusion | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| DOE (dyspnea on exertion) | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Fatigue | General disorders | CTC2.0 | Systematic Assessment |
| |
| Hypotension | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Infection: EBV (Epstein Barr virus) reactivation | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Death/Infection with unknown ANC (absolute neutrophil count) | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Death/Infection without neutropenia | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Infection without neutropenia | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Infection with grade 3 or 4 neutropenia | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Death/Fever/Neutropenia | General disorders | CTC2.0 | Systematic Assessment |
| |
| Fever/neutropenia | General disorders | CTC2.0 | Systematic Assessment |
| |
| Fever without neutropenia | General disorders | CTC2.0 | Systematic Assessment |
| |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Rash desquamation | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Surgery:GI (gastrointestinal) intussusception | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| SVT (supraventricular tachycardia) | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Tumor flare | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | CTC2.0 | Systematic Assessment |
| |
| Wound infectious | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Ventricular arrhythmia | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Infection with unknown ANC | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Infection: septic arthritis | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Bili increased | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Ileus | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Death related to 2nd cancer:EBV (Epstein Barr virus) lymphoma | General disorders | CTC2.0 | Systematic Assessment |
| |
| Death:cardiac arrest | General disorders | CTC2.0 | Systematic Assessment |
| |
| Febrile neutropenia | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Hemolysis | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Infection with grade 3 or 4 ANC | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Infection:catheter | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Melana | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Platelet | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Prolonged QTc | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Thromboembolic event | Vascular disorders | CTC2.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Peripheral motor neuropathy | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Death progressive disease | General disorders | CTC2.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Anorexia | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Fatigue | General disorders | CTC2.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Hyperglycemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hypokalemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hypermagnesemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hyperuricemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hyponatremia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hypotension | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Lymphocyte count | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Neutrophil count | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Hypoalbuminemia | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Hypocalcemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Dysgeusia | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Hypophosphatemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Platelet count decreased | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Diarrhea | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Fever | General disorders | CTC2.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Bilirubin increased | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Hypomagnesemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| AST (aspartate transaminase)/SGOT (serum glutamic oxaloacetic transaminase) | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Acidosis | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Activated PTT (partial thromboplastin time) | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Acute kidney injury | Injury, poisoning and procedural complications | CTC2.0 | Systematic Assessment |
| |
| ALT (alanine aminotransferase) | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Alk phos | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Allergic reaction | Immune system disorders | CTC2.0 | Systematic Assessment |
| |
| Allergic rhinitis | Immune system disorders | CTC2.0 | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Anaphylaxis | Immune system disorders | CTC2.0 | Systematic Assessment |
| |
| Anxiety | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Arthritis | Musculoskeletal and connective tissue disorders | CTC2.0 | Systematic Assessment |
| |
| AST (aspartate aminotransferase) | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Bloating | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Blurred vision | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Bronchopulmonary hemorrhage | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Cardiac disorder:T wave | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Cataract | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Catheter-related infection | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Chills | General disorders | CTC2.0 | Systematic Assessment |
| |
| Phlebitis | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Cholesterol high | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Conduction disorder | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Conjunctivitis | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| CPK (creatine phosphokinase) | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Creatinine increased | Renal and urinary disorders | CTC2.0 | Systematic Assessment |
| |
| Dehydration | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Depression | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Dry mouth | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Dry skin | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Dyspepsia on exertion | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Ear pain | Ear and labyrinth disorders | CTC2.0 | Systematic Assessment |
| |
| Electrocardiogram QT corrected interval prolonged | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Erectile dysfunction | Reproductive system and breast disorders | CTC2.0 | Systematic Assessment |
| |
| Erythema multiforme | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Esophagitis | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Eye disorder | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Eye pain | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Febrile neutropenia | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Flushing | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| GERD (gastroesophageal reflux disease) | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| GGT (gamma glutamyltransferase) increased | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Hematuria | Renal and urinary disorders | CTC2.0 | Systematic Assessment |
| |
| Hemolysis | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Viral hepatitis | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Hot flashes | Endocrine disorders | CTC2.0 | Systematic Assessment |
| |
| Hypercalcemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hyperhidrosis | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Hyperkalemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hypernatremia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hypertension | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Hypertriglyceridemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hypoglycemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hypophosphatemia | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Ileus | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Infections | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| INR (International Normalized Ratio) increased | Investigations | CTC2.0 | Systematic Assessment |
| |
| Insomnia | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Keratitis | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Lower GI hemorrhage | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Mucositis oral | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Lung infection | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Musculoskeletal and connective tissue disorder | Musculoskeletal and connective tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Nail loss | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Neuralgia | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Non cardiac chest pain | Musculoskeletal and connective tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Oral pain/mucositis | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Pain | General disorders | CTC2.0 | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Paresthesia | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Peripheral ischemia | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Peripheral sensory neuropathy | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Proteinuria | Renal and urinary disorders | CTC2.0 | Systematic Assessment |
| |
| Pruritis | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Psychosis | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Pulmonary fibrosis | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Rash-maculo-papular | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Rectal hemorrhage | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| UTI (urinary tract infection) | Renal and urinary disorders | CTC2.0 | Systematic Assessment |
| |
| Vaginal mucositis | Reproductive system and breast disorders | CTC2.0 | Systematic Assessment |
| |
| URI (upper respiratory infection) | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Sinus bradycardia | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Sinus tachycardia | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Stevens-Johnson syndrome | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| SVT (supraventricular tachycardia) | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Syncope | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Thromboembolic event | Vascular disorders | CTC2.0 | Systematic Assessment |
| |
| Tooth infection | Infections and infestations | CTC2.0 | Systematic Assessment |
| |
| Tremor | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Tumor flare | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | CTC2.0 | Systematic Assessment |
| |
| Urinary frequency | Renal and urinary disorders | CTC2.0 | Systematic Assessment |
| |
| Urinary retention | Renal and urinary disorders | CTC2.0 | Systematic Assessment |
| |
| Ventricular arrhythmia | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Vision changes | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Voice alteration/hoarseness | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Watering eyes | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Weight gain | General disorders | CTC2.0 | Systematic Assessment |
| |
| Weight loss | General disorders | CTC2.0 | Systematic Assessment |
| |
| Wheezing | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| WBC (white blood cell) decreased | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Wound dehiscence | Injury, poisoning and procedural complications | CTC2.0 | Systematic Assessment |
| |
| Skin decubitus ulcer | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Urine incontinence | Renal and urinary disorders | CTC2.0 | Systematic Assessment |
| |
| Serum amylase increased | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Lipase increased | Metabolism and nutrition disorders | CTC2.0 | Systematic Assessment |
| |
| Memory impairment | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Peripheral motor neuropathy | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Pancreatitis | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | CTC2.0 | Systematic Assessment |
| |
| Rash acneiform | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Confusion | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Dry eye | Eye disorders | CTC2.0 | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | CTC2.0 | Systematic Assessment |
| |
| Euphoria | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Extrapyramidal disorder | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Alkalosis | Congenital, familial and genetic disorders | CTC2.0 | Systematic Assessment |
| |
| Anxiety | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Ataxia | Nervous system disorders | CTC2.0 | Systematic Assessment |
| |
| Troponin I increased | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Troponin T increased | Cardiac disorders | CTC2.0 | Systematic Assessment |
| |
| Injection site reaction | Skin and subcutaneous tissue disorders | CTC2.0 | Systematic Assessment |
| |
| Lymphocyte count decreased | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Neutrophil count decreased | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| ALT(alanine aminotransferase)/SGPT (serum glutamic pyruvic transaminase) | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Alkaline phosphokinase increased | Hepatobiliary disorders | CTC2.0 | Systematic Assessment |
| |
| Partial thromboplastin time (PTT) | Blood and lymphatic system disorders | CTC2.0 | Systematic Assessment |
| |
| Pericardial effusion | Cardiac disorders | CTC2.0 | Systematic Assessment |
|
7 cohorts were consolidated for submission to the Food and Drug Administration (FDA) into the peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) groups, thus they are presented in this format.
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Kieron Dunleavy | National Cancer Institute | 301-435-1007 | DunleavK@mail.nih.gov |
| ID | Term |
|---|---|
| D016410 | Lymphoma, T-Cell, Cutaneous |
| D016411 | Lymphoma, T-Cell, Peripheral |
| D012751 | Sezary Syndrome |
| D009182 | Mycosis Fungoides |
| ID | Term |
|---|---|
| D016399 | Lymphoma, T-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C087123 | romidepsin |
Not provided
Not provided
Not provided
| >=65 years |
|
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Australia |
|
| Partial Response |
|
| Stable Disease |
|
| Progressive disease |
|
| Not Evaluable |
|
|
|
|
|
|
|
| Participants |
|
|
|
|